Corvion

About Corvion

Corvion Inc. is a pre-clinical stage medical device company operating in the mechanical circulatory support market, with a focus on patients with end-stage heart failure. Founded in 2012 by Greg S. Aber and formerly known as EverHeart Systems, the company is headquartered in Webster, Texas. Aber, the company's CEO, has a background as a NASA engineer where he developed pump designs for the Space Shuttle and co-invented the first successful centrifugal heart pump with Dr. Michael DeBakey. His experience also includes roles at Boston Scientific and Cyberonics, contributing to his over 50 granted patents.

The company is developing a fully implantable Left Ventricular Assist Device (LVAD) designed to address the limitations of existing technologies. Corvion's primary product is a high-efficiency rotary blood pump that is reportedly three times more efficient than competing devices, requiring significantly less power. This efficiency is achieved through a hybrid magnetically levitated impeller and a high-efficiency motor, which results in less blood damage. The low power consumption enables the use of a small, implantable battery and controller unit that can power the pump for up to 12 hours independently, allowing patients to be untethered from external equipment.

A key feature of Corvion's system is its transcutaneous wireless charging technology. A lightweight external mobile charger sends power through the skin to recharge the internal battery in about two hours, eliminating the need for a percutaneous driveline and thereby reducing the risk of infection. The system also includes a handheld patient monitor for system status and alarms. The company, which has received an FDA Breakthrough Device Designation, is currently in the animal trial phase and aims to begin human trials soon. Corvion's business model appears to be B2B2C, targeting a potential $15 billion untapped LVAD market by offering a solution that improves patient mobility and quality of life.